Where Pay-For-Delay Stands 3 Years After Actavis
Three years after the U.S. Supreme Court ruled that brand-name drugmakers' payments to generics companies in patent settlements can raise antitrust concerns, courts are lining up behind the idea that an...To view the full article, register now.
Already a subscriber? Click here to view full article